Stock BIOR BIORA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Biora Therapeutics, Inc.

Equities

BIOR

US74319F3055

Real-time Estimate Cboe BZX
Other stock markets
 07:14:40 29/04/2024 pm IST 		5-day change 1st Jan Change
0.625 USD -0.43% Intraday chart for Biora Therapeutics, Inc. +2.07% -53.50%
04/04 Biora Therapeutics, Inc. Achieves Positive Interim Results for Clinical Trial of BT-600, Advancing NaviCap Platform Development CI
03/04 Athyrium Capital Management Engages in Discussions with Biora Therapeutics CI

Evolution of the average Target Price on Biora Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

4187750c8f10e4b0dc4e62a1afc70e6.XsoouBHDCUmKVi0tcS3wplo9p78gdQrEMCD0lCgHZHg.aq1ciyOXbT-yOVVJEkuKyh5S69lkG2KVYkm3y08qDS43_hiNdKd7cN84GQ~f79717a3a3c348f13c0eeb29b88e4a66

Analyst Recommendations on Biora Therapeutics, Inc.

HC Wainwright Adjusts Biora Therapeutics Price Target to $50 From $65, Maintains Buy Rating MT
HC Wainwright Adjusts Price Target on Biora Therapeutics to $6 From $4, Reiterates Buy Rating MT
CORRECTION : BTIG Analyst Assumes Biora Therapeutics at Buy, Price Target $4 MT
BTIG Assumes Progenity at Buy, Price Target $12 MT
PROGENITY : HC Wainwright Starts Progenity at Buy with $4 Price Target MT
PROGENITY : Raymond James Downgrades Progenity to Market Perform From Outperform MT
PROGENITY : Piper Sandler Adjusts Progenity's Price Target to $3 From $8, Maintains Overweight Rating MT
PROGENITY : Baird Lowers Progenity to Neutral From Outperform, Price Target to $2 From $4 MT
PROGENITY : Wells Fargo Adjusts Progenity PT to $2 From $4, Maintains Underweight Rating MT
PROGENITY : Raymond James Adjusts Price Target on Progenity to $7 From $10, Maintains Outperform Rating MT
PROGENITY : Baird Adjusts Progenity's Price Target to $4 From $6, Keeps Outperform Rating MT
PROGENITY : Wells Fargo Downgrades Progenity to Underweight From Overweight, Adjusts Price Target to $5 From $11 MT
PROGENITY : Raymond James Adjusts Progenity PT to $10 From $15, Maintains Outperform Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.6277 USD
Average target price
10.3 USD
Spread / Average Target
+1,540.91%
High Price Target
15 USD
Spread / Highest target
+2,289.68%
Low Price Target
5.6 USD
Spread / Lowest Target
+792.15%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Biora Therapeutics, Inc.

HC Wainwright
BTIG
Piper Sandler
Baird
Raymond James
Wells Fargo Securities

Ratings for Biora Therapeutics, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. BIOR Stock
  4. Consensus Biora Therapeutics, Inc.